BioVie nears data readout for potential first treatment targeting long COVID symptoms.

BioVie Inc is advancing its clinical trial for a novel treatment aimed at long COVID, a condition affecting around 17 million Americans with symptoms like brain fog and fatigue. The company has secured a $13 million grant, making it unique in receiving such funding for this condition. Patient enrollment is nearly complete, with top-line trial results expected by the end of summer. Positive data could position BioVie as a leader in a market with no approved long COVID therapies, addressing a significant unmet medical need.